追踪政府免疫规划支出:联合报告表、国家卫生账户、多年度计划与共同融资数据
本研究比较了WHO/UNICEF联合报告表、国家多年度计划、Gavi共同融资数据和WHO国家卫生账户中政府免疫规划支出的一致性。结果显示常规免疫支出在多年度计划中约为联合报告表的两倍,疫苗支出在联合报告表和多年度计划中均高于Gavi共同融资至少两倍,提示数据来源间存在差异但部分指标具有可比性。
要点
- 多年度计划报告的常规免疫支出约为联合报告表的两倍。
- 联合报告表与NHA的常规免疫支出具有可比性。
- 联合报告表和多年度计划的疫苗支出均高于Gavi共同融资至少两倍。
核心结论
- 现有免疫支出报告机制总体有一定可信度,但不同数据来源间存在显著差异,需谨慎使用并改进报告质量。
研究设计与样本
- 利用WHO/UNICEF联合报告表、国家多年度计划、Gavi共同融资数据和WHO国家卫生账户的最新可用数据,比较常规免疫和疫苗支出的一致性、趋势及漏报情况。
主要发现
- 多年度计划的常规免疫支出接近联合报告表的两倍(rho=0.64,95%CI 0.53至0.77),约为NHA的四倍(rho=3.71,95%CI 1.00至13.87)。
- 联合报告表的常规免疫支出与NHA相当(rho=1.30,95%CI 0.97至1.75)。
- 联合报告表的疫苗支出与多年度计划相当(rho=0.97,95%CI 0.84至1.12)。
- 联合报告表和多年度计划的疫苗支出均高于Gavi共同融资至少两倍(rho=2.66,95%CI 2.45至2.89和rho=2.66,95%CI 2.15至3.30)。
临床怎么用
- 使用免疫支出数据时应考虑不同来源间的差异,并推动政府提高疫苗和免疫支出报告的可靠性、全面性和准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coverage rates for immunization have dropped in lower income countries during the COVID-19 pandemic, raising concerns regarding potential outbreaks and premature death. In order to re-invigorate immunization service delivery, sufficient financing must be made available from all sources, and particularly from government resources. This study utilizes the most recent data available to provide an updated comparison of available data sources on government spending on immunization. METHODS: We examined data from WHO/UNICEF's Joint Reporting Form (JRF), country Comprehensive Multi-Year Plan (cMYP), country co-financing data for Gavi, and WHO National Health Accounts (NHA) on government spending on immunization for consistency by comparing routine and vaccine spending where both values were reported. We also examined spending trends across time, quantified underreporting and utilized concordance analyses to assess the magnitude of difference between the data sources. RESULTS: Routine immunization spending reported through the cMYP was nearly double that reported through the JRF (rho = 0.64, 95% 0.53 to 0.77) and almost four times higher than that reported through the NHA on average (rho = 3.71, 95% 1.00 to 13.87). Routine immunization spending from the JRF was comparable to spending reported in the NHA (rho = 1.30, 95% 0.97 to 1.75) and vaccine spending from the JRF was comparable to that from the cMYP data (rho = 0.97, 95% 0.84 to 1.12). Vaccine spending from both the JRF and cMYP was higher than Gavi co-financing by a at least two (rho = 2.66, 95% 2.45 to 2.89) and (rho = 2.66, 95% 2.15 to 3.30), respectively. IMPLICATIONS: Overall, our comparative analysis provides a degree of confidence in the validity of existing reporting mechanisms for immunization spending while highlighting areas for potential improvements. Users of these data sources should factor these into consideration when utilizing the data. Additionally, partners should work with governments to encourage more reliable, comprehensive, and accurate reporting of vaccine and immunization spending.
引用
- Ikilezi G, Bachmeier SD, Cogswell IE, et al. Tracking government spending on immunization: The joint reporting forms, national health accounts, comprehensive multi-year plans and co-financing data. Vaccine. 2021. PMID: 34020816. doi:10.1016/j.vaccine.2021.04.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。